{
  "@context": "aku-v2",
  "@type": "procedure",
  "@id": "wsmg:health-sciences/medicine/hematology/hem-037",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:58:35.000Z",
    "modified": "2026-01-11T02:58:00.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "quality-agent"
    ],
    "confidence": 0.96,
    "status": "validated",
    "language": "en",
    "licenses": ["CC-BY-4.0"]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/hematology",
    "subdomain": "antithrombotic-therapy",
    "type": "procedure",
    "difficulty": "intermediate",
    "importance": "critical",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Antiplatelet Therapy",
    "summary": "Antiplatelet agents inhibit platelet activation and aggregation to prevent arterial thrombosis in conditions like coronary artery disease, cerebrovascular disease, and peripheral arterial disease. Major classes include COX-1 inhibitors (aspirin), P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor), and GPIIb/IIIa inhibitors. Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is standard after ACS and coronary stenting. Key considerations include bleeding risk, drug interactions, and perioperative management.",
    "key_points": [
      "Aspirin: irreversible COX-1 inhibition → blocks TXA2 → lasts platelet lifetime (7-10 days)",
      "P2Y12 inhibitors: block ADP receptor → clopidogrel, prasugrel, ticagrelor",
      "DAPT: Aspirin + P2Y12 inhibitor after ACS and coronary stenting",
      "Duration: 6-12 months after stent; 12 months after ACS; may extend if high ischemic risk",
      "Bleeding risk: Assess with PRECISE-DAPT or DAPT scores",
      "Perioperative: Hold clopidogrel 5-7 days; ticagrelor 3-5 days before surgery"
    ],
    "statement": "Antiplatelet therapy uses aspirin and P2Y12 inhibitors to prevent arterial thrombosis, with dual antiplatelet therapy standard after ACS and coronary stenting, balanced against bleeding risk and managed perioperatively with appropriate drug discontinuation intervals.",
    "explanation": {
      "intuition": "Platelets are the first responders to arterial injury. Aspirin prevents platelets from releasing their 'call to arms' signal (thromboxane A2), while P2Y12 inhibitors block the amplification signal (ADP). Using both creates a stronger anti-clotting effect needed after stents and heart attacks.",
      "key_insight": "Aspirin's effect is irreversible and lasts the platelet's lifetime (~10 days). This means even after stopping aspirin, full platelet function won't return until new platelets are made. In contrast, ticagrelor binds reversibly, so its effect wears off faster (~3-5 days).",
      "technical_details": "Aspirin acetylates COX-1 at Ser530, irreversibly blocking TXA2 synthesis. Clopidogrel and prasugrel are thienopyridine prodrugs requiring hepatic activation (CYP2C19 for clopidogrel). Ticagrelor is a cyclopentyltriazolopyrimidine that directly and reversibly inhibits P2Y12. GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) block final common pathway of aggregation."
    },
    "definitions_glossary": {
      "antiplatelet_agent": "Drug inhibiting platelet activation or aggregation",
      "aspirin": "Acetylsalicylic acid; irreversible COX-1 inhibitor blocking TXA2 synthesis",
      "thromboxane_A2": "TXA2; platelet-derived prostaglandin promoting aggregation and vasoconstriction",
      "P2Y12_receptor": "Platelet ADP receptor; target of clopidogrel, prasugrel, ticagrelor",
      "clopidogrel": "Thienopyridine prodrug; irreversible P2Y12 inhibitor",
      "prasugrel": "Thienopyridine prodrug; more potent P2Y12 inhibitor; contraindicated in prior stroke",
      "ticagrelor": "Direct-acting reversible P2Y12 inhibitor; twice daily dosing",
      "cangrelor": "IV P2Y12 inhibitor for procedural use; rapid onset and offset",
      "DAPT": "Dual antiplatelet therapy; aspirin plus P2Y12 inhibitor",
      "GPIIbIIIa_inhibitor": "IV agents blocking final pathway of platelet aggregation",
      "stent_thrombosis": "Thrombotic occlusion of coronary stent; prevented by DAPT",
      "CYP2C19": "Cytochrome P450 enzyme activating clopidogrel; polymorphisms affect response"
    }
  },
  "clinical_features": {
    "pharmacology": {
      "aspirin": {
        "mechanism": "Irreversibly acetylates COX-1; blocks TXA2 synthesis",
        "effect_duration": "Platelet lifetime (7-10 days)",
        "dosing": "75-100 mg daily for prevention; 160-325 mg loading",
        "onset": "30-60 minutes",
        "note": "Enteric coating delays onset but not used for ACS"
      },
      "P2Y12_inhibitors": {
        "clopidogrel": {
          "brand": "Plavix",
          "mechanism": "Irreversible; requires CYP2C19 activation",
          "loading": "300-600 mg",
          "maintenance": "75 mg daily",
          "genetic_testing": "CYP2C19 poor metabolizers have reduced effect",
          "drug_interaction": "PPIs (especially omeprazole) may reduce efficacy"
        },
        "prasugrel": {
          "brand": "Effient",
          "mechanism": "Irreversible; more complete activation than clopidogrel",
          "loading": "60 mg",
          "maintenance": "10 mg daily (5 mg if <60 kg)",
          "contraindications": "Prior stroke/TIA; age ≥75; weight <60 kg (higher bleeding)"
        },
        "ticagrelor": {
          "brand": "Brilinta",
          "mechanism": "Reversible direct P2Y12 inhibition; no prodrug activation",
          "loading": "180 mg",
          "maintenance": "90 mg BID (60 mg BID for extended therapy)",
          "side_effects": "Dyspnea, ventricular pauses; avoid with strong CYP3A4 inhibitors",
          "aspirin_dose": "Requires low-dose aspirin (81 mg); high-dose reduces efficacy"
        },
        "cangrelor": {
          "brand": "Kengreal",
          "route": "IV only",
          "mechanism": "Reversible; rapid onset and offset",
          "use": "Periprocedural when oral P2Y12 cannot be given",
          "half_life": "3-6 minutes"
        }
      },
      "GPIIbIIIa_inhibitors": {
        "agents": ["Abciximab (ReoPro)", "Eptifibatide (Integrilin)", "Tirofiban (Aggrastat)"],
        "mechanism": "Block GPIIb/IIIa receptor; prevent fibrinogen binding",
        "use": "PCI-related high-risk situations",
        "route": "IV only",
        "complications": "Bleeding, thrombocytopenia"
      }
    },
    "indications": {
      "coronary_artery_disease": {
        "ACS_NSTEMI_UA": "DAPT: Aspirin + ticagrelor or prasugrel (preferred) or clopidogrel",
        "STEMI": "DAPT: Aspirin + ticagrelor or prasugrel preferred",
        "stable_CAD": "Aspirin monotherapy; DAPT if recent stent",
        "post_PCI": "DAPT duration based on stent type and bleeding risk"
      },
      "cerebrovascular_disease": {
        "acute_stroke": "Aspirin within 24-48 hours",
        "secondary_prevention": "Aspirin or clopidogrel monotherapy",
        "DAPT_stroke": "Short-term DAPT (21-30 days) for minor stroke/high-risk TIA"
      },
      "peripheral_arterial_disease": {
        "symptomatic_PAD": "Aspirin or clopidogrel monotherapy",
        "post_revascularization": "DAPT for limited duration"
      }
    },
    "DAPT_duration": {
      "after_DES": {
        "minimum": "6 months",
        "standard": "12 months after ACS",
        "extended": ">12 months if high ischemic, low bleeding risk",
        "shortened": "1-3 months if high bleeding risk"
      },
      "decision_tools": {
        "DAPT_score": "Predicts benefit of extended DAPT (ischemic vs bleeding)",
        "PRECISE_DAPT": "Predicts bleeding risk; guides duration"
      }
    },
    "adverse_effects": {
      "bleeding": {
        "major_bleeding": "2-4% per year on DAPT",
        "GI_bleeding": "Common; consider PPI",
        "intracranial": "Rare but serious"
      },
      "drug_specific": {
        "aspirin": "GI upset, tinnitus (toxicity), Reye syndrome (children)",
        "clopidogrel": "TTP (rare)",
        "ticagrelor": "Dyspnea (10-15%), bradycardia, elevated uric acid"
      }
    },
    "perioperative_management": {
      "elective_surgery": {
        "aspirin": "Continue if cardiovascular benefit outweighs bleeding",
        "clopidogrel": "Hold 5-7 days before surgery",
        "prasugrel": "Hold 7-10 days before surgery",
        "ticagrelor": "Hold 3-5 days before surgery"
      },
      "urgent_surgery": {
        "platelet_transfusion": "May help reverse aspirin; less effective for P2Y12 inhibitors",
        "DDAVP": "May improve platelet function"
      },
      "stent_considerations": {
        "minimum_DAPT": "Do not stop prematurely after stent",
        "high_risk_period": "First 6 weeks post-DES highest stent thrombosis risk"
      }
    },
    "resistance_and_variability": {
      "aspirin_resistance": {
        "definition": "Inadequate TXA2 suppression despite therapy",
        "causes": ["Non-compliance", "Drug interactions (NSAIDs)", "True resistance (rare)"]
      },
      "clopidogrel_resistance": {
        "prevalence": "15-40% of patients",
        "causes": ["CYP2C19 polymorphisms", "Drug interactions (PPIs)", "Diabetes", "Obesity"],
        "testing": "Platelet function testing or CYP2C19 genotyping",
        "management": "Consider prasugrel or ticagrelor"
      }
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Antiplatelet Therapy"
    },
    "altLabel": [
      {"@language": "en", "@value": "Platelet Inhibition"},
      {"@language": "en", "@value": "DAPT"},
      {"@language": "en", "@value": "Dual Antiplatelet Therapy"}
    ],
    "definition": {
      "@language": "en",
      "@value": "Use of agents inhibiting platelet activation and aggregation to prevent arterial thrombosis in cardiovascular disease"
    },
    "notation": "hem-037",
    "scopeNote": {
      "@language": "en",
      "@value": "Essential after ACS and coronary stenting; includes aspirin and P2Y12 inhibitors"
    }
  },
  "relationships": {
    "skos:broader": [
      {
        "@id": "wsmg:health-sciences/medicine/hematology/antithrombotic-therapy",
        "skos:prefLabel": "Antithrombotic Therapy"
      }
    ],
    "skos:related": [
      {
        "@id": "wsmg:health-sciences/medicine/cardiology/acute-coronary-syndrome",
        "skos:prefLabel": "Acute Coronary Syndrome"
      },
      {
        "@id": "wsmg:health-sciences/medicine/cardiology/coronary-stenting",
        "skos:prefLabel": "Coronary Stenting"
      }
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Antiplatelet_drug"
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "372756006",
      "uri": "http://snomed.info/id/372756006",
      "description": "Antiplatelet agent"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D010975",
      "uri": "http://id.nlm.nih.gov/mesh/D010975",
      "description": "Platelet Aggregation Inhibitors"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "ATC",
      "codeValue": "B01AC",
      "description": "Platelet aggregation inhibitors"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Compare mechanisms of aspirin and P2Y12 inhibitors",
      "Select appropriate P2Y12 inhibitor based on patient characteristics",
      "Determine DAPT duration based on ischemic and bleeding risk",
      "Manage antiplatelet therapy perioperatively",
      "Recognize and address clopidogrel resistance"
    ],
    "clinical_pearls": [
      "Aspirin is irreversible - effect lasts 7-10 days (platelet lifetime)",
      "Prasugrel contraindicated in prior stroke/TIA - increases bleeding",
      "Ticagrelor requires low-dose aspirin (81 mg) - high dose reduces efficacy",
      "CYP2C19 poor metabolizers have reduced clopidogrel effect",
      "Hold clopidogrel 5-7 days, ticagrelor 3-5 days before surgery"
    ],
    "board_yield": "HIGH",
    "estimated_time": "25min",
    "target_audience": [
      "medical_students",
      "internal_medicine_residents",
      "cardiologists"
    ],
    "common_misconceptions": [
      "All P2Y12 inhibitors are the same - they differ in onset, reversibility, and potency",
      "Aspirin is always continued for surgery - depends on bleeding vs ischemic risk",
      "PPIs always interact with clopidogrel - data is mixed; omeprazole has strongest interaction"
    ]
  },
  "prerequisites": [
    {
      "@id": "wsmg:health-sciences/medicine/hematology/platelet-physiology",
      "skos:prefLabel": "Platelet Physiology"
    }
  ],
  "related_concepts": [
    "aspirin",
    "clopidogrel",
    "ticagrelor",
    "coronary stent",
    "acute coronary syndrome"
  ],
  "evidence": {
    "citations": [
      {
        "authors": "Levine GN, Bates ER, Bittl JA, et al.",
        "title": "2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease",
        "journal": "Circulation",
        "year": 2016,
        "volume": "134",
        "pages": "e123-e155",
        "doi": "10.1161/CIR.0000000000000404"
      }
    ],
    "confidence_rationale": "Well-established guidelines from major trials and societies"
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-11T02:58:00.000Z",
    "sources": [
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill, 2022.",
        "type": "textbook",
        "year": 2022,
        "isbn": "978-1264268504",
        "relevance": "Standard medical reference"
      },
      {
        "source": "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization",
        "type": "guideline",
        "year": 2021,
        "relevance": "Current clinical guidelines"
      }
    ]
  },
  "quality_assessment": {
    "content_quality_score": 0.95,
    "completeness": 0.96,
    "accuracy": 0.96,
    "clarity": 0.95,
    "clinical_relevance": 0.97,
    "last_assessed": "2026-01-11T02:58:00.000Z"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Antiplatelet_drug",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q2858527"
}